EA200970595A1 - Производные замещенных индазолов, активные в качестве ингибиторов киназ - Google Patents
Производные замещенных индазолов, активные в качестве ингибиторов киназInfo
- Publication number
- EA200970595A1 EA200970595A1 EA200970595A EA200970595A EA200970595A1 EA 200970595 A1 EA200970595 A1 EA 200970595A1 EA 200970595 A EA200970595 A EA 200970595A EA 200970595 A EA200970595 A EA 200970595A EA 200970595 A1 EA200970595 A1 EA 200970595A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- derivatives
- substituted
- indazols
- active
- kinaz
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 150000002473 indoazoles Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Описаны производные замещенных индазолов формулы (I) и их фармацевтически приемлемые соли, указываемые в описании, способ их получения и содержащие их фармацевтические композиции; соединения изобретения могут быть применимыми в терапии при лечении заболеваний, связанных с нарушенной активностью протеинкиназ, подобных раку.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06126701 | 2006-12-20 | ||
PCT/EP2007/063998 WO2008074749A1 (en) | 2006-12-20 | 2007-12-14 | Indazole derivatives as kinase inhibitors for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970595A1 true EA200970595A1 (ru) | 2010-02-26 |
EA017852B1 EA017852B1 (ru) | 2013-03-29 |
Family
ID=39245139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970595A EA017852B1 (ru) | 2006-12-20 | 2007-12-14 | Производные замещенных индазолов, активные в качестве ингибиторов киназ |
Country Status (15)
Country | Link |
---|---|
US (1) | US8114865B2 (ru) |
EP (1) | EP2120932B1 (ru) |
JP (1) | JP5302896B2 (ru) |
CN (1) | CN101594862B (ru) |
AU (1) | AU2007336335B8 (ru) |
BR (1) | BRPI0720589A2 (ru) |
CA (1) | CA2673095C (ru) |
DK (1) | DK2120932T3 (ru) |
EA (1) | EA017852B1 (ru) |
ES (1) | ES2509820T3 (ru) |
MX (1) | MX2009006401A (ru) |
PL (1) | PL2120932T3 (ru) |
PT (1) | PT2120932E (ru) |
SI (1) | SI2120932T1 (ru) |
WO (1) | WO2008074749A1 (ru) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
US8183381B2 (en) * | 2007-07-19 | 2012-05-22 | Metabolex Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
NZ583450A (en) | 2007-07-20 | 2012-05-25 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
ES2630026T3 (es) * | 2008-12-18 | 2017-08-17 | Nerviano Medical Sciences S.R.L. | Derivados indazólicos sustituidos activos como inhibidores de cinasa |
JO2860B1 (en) | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
CN102666553B (zh) | 2009-10-01 | 2015-05-06 | 赛马拜制药公司 | 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐 |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EA201290919A1 (ru) * | 2010-03-16 | 2013-03-29 | Дана-Фарбер Кэнсер Инститьют, Инк. | Индазольные соединения и их применение |
WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
FR2970967B1 (fr) | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
ES2611779T3 (es) * | 2011-05-12 | 2017-05-10 | Nerviano Medical Sciences S.R.L. | Derivados de indazol sustituidos activos como inhibidores de quinasas |
JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | N−置換ヘテロシクリルカルボキサミド類 |
JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
ES2755719T3 (es) * | 2012-04-05 | 2020-04-23 | Nerviano Medical Sciences Srl | Nuevos agentes alquilantes |
KR102151963B1 (ko) * | 2012-05-23 | 2020-09-07 | 네르비아노 메디칼 사이언시스 에스.알.엘. | N-[5-(3,5-디플루오로-벤질)-1h-인다졸-3-일]-4-(4-메틸-피페라진-1-일)-2-(테트라하이드로-피란-4-일아미노)-벤즈아미드의 제조 방법 |
KR101936851B1 (ko) * | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체 |
EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
JP6371284B2 (ja) | 2012-08-22 | 2018-08-08 | コーネル ユニヴァーシティー | ファスシンを阻害する方法 |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2015110467A1 (en) * | 2014-01-23 | 2015-07-30 | Nerviano Medical Sciences S.R.L. | Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides |
TWI672141B (zh) * | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
ES2868882T3 (es) | 2014-02-20 | 2021-10-22 | Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec | Compuestos y métodos para inhibir fascina |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN104530045A (zh) * | 2015-01-14 | 2015-04-22 | 中国药科大学 | 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途 |
WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
JP7061068B2 (ja) | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | 癌治療のための併用薬 |
JP2019527693A (ja) | 2016-08-03 | 2019-10-03 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物 |
AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
US10508105B2 (en) | 2017-08-16 | 2019-12-17 | Vanderbilt University | Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
CN110452176A (zh) * | 2018-05-07 | 2019-11-15 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ531765A (en) * | 2001-09-26 | 2006-02-24 | Pharmacia Italia S | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
CA2517517C (en) * | 2003-03-03 | 2012-12-18 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
CA2599987A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
CL2009001158A1 (es) * | 2008-05-15 | 2009-10-23 | Nerviano Medical Sciences Srl | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. |
-
2007
- 2007-12-14 PL PL07857632T patent/PL2120932T3/pl unknown
- 2007-12-14 DK DK07857632.9T patent/DK2120932T3/da active
- 2007-12-14 PT PT78576329T patent/PT2120932E/pt unknown
- 2007-12-14 CA CA2673095A patent/CA2673095C/en not_active Expired - Fee Related
- 2007-12-14 JP JP2009542015A patent/JP5302896B2/ja active Active
- 2007-12-14 BR BRPI0720589-9A patent/BRPI0720589A2/pt active Search and Examination
- 2007-12-14 WO PCT/EP2007/063998 patent/WO2008074749A1/en active Application Filing
- 2007-12-14 US US12/520,387 patent/US8114865B2/en active Active
- 2007-12-14 EA EA200970595A patent/EA017852B1/ru not_active IP Right Cessation
- 2007-12-14 SI SI200731506T patent/SI2120932T1/sl unknown
- 2007-12-14 AU AU2007336335A patent/AU2007336335B8/en not_active Ceased
- 2007-12-14 CN CN200780049818.0A patent/CN101594862B/zh active Active
- 2007-12-14 EP EP07857632.9A patent/EP2120932B1/en active Active
- 2007-12-14 MX MX2009006401A patent/MX2009006401A/es active IP Right Grant
- 2007-12-14 ES ES07857632.9T patent/ES2509820T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
AU2007336335A2 (en) | 2009-08-06 |
JP2010530840A (ja) | 2010-09-16 |
US8114865B2 (en) | 2012-02-14 |
AU2007336335B2 (en) | 2013-05-30 |
CA2673095C (en) | 2016-03-15 |
CA2673095A1 (en) | 2008-06-26 |
DK2120932T3 (da) | 2014-10-13 |
JP5302896B2 (ja) | 2013-10-02 |
US20100197665A1 (en) | 2010-08-05 |
CN101594862B (zh) | 2015-11-25 |
PL2120932T3 (pl) | 2015-02-27 |
EA017852B1 (ru) | 2013-03-29 |
SI2120932T1 (sl) | 2014-09-30 |
WO2008074749A1 (en) | 2008-06-26 |
WO2008074749A9 (en) | 2009-05-07 |
ES2509820T3 (es) | 2014-10-20 |
CN101594862A (zh) | 2009-12-02 |
EP2120932A1 (en) | 2009-11-25 |
MX2009006401A (es) | 2009-06-23 |
EP2120932B1 (en) | 2014-07-09 |
AU2007336335A8 (en) | 2014-07-24 |
BRPI0720589A2 (pt) | 2014-02-25 |
AU2007336335A1 (en) | 2008-06-26 |
PT2120932E (pt) | 2014-10-10 |
AU2007336335B8 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
HK1136292A1 (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
MX2007005546A (es) | Tiazoles de 5-heteroarilo y su uso como inhibidores p13k. | |
MX2008012422A (es) | Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa. | |
PA8622801A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
ATE496899T1 (de) | Tetrahydro- und dihydrochinazolinone | |
CU20060152A7 (es) | Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa | |
CU23596A3 (es) | Derivados de pirazol-quinazolina y proceso para su preparación | |
EA201990219A3 (ru) | Ингибиторы mek и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |